Company Overview and News

0
GNMK / GenMark Diagnostics, Inc. 8-K (Current Report)

2018-08-02 sec.gov
Document UNITED STATES
GNMK

0
GenMark Diagnostics, Inc. (GNMK) CEO Hany Massarany on Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
GenMark Diagnostics, Inc. (NASDAQ:GNMK) Q2 2018 Results Earnings Conference Call July 30, 2018 4:30 PM ET
GNMK

2
GenMark Diagnostics (GNMK) Reports Q2 Loss, Tops Revenue Estimates

2018-07-30 zacks
GenMark Diagnostics (GNMK - Free Report) just came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.
ALGN GNMK

0
GNMK / GenMark Diagnostics, Inc. 10-Q (Quarterly Report)

2018-07-30 sec.gov
Document Table of Contents
GNMK

0
GNMK / GenMark Diagnostics, Inc. 8-K (Current Report)

2018-07-30 sec.gov
Document UNITED STATES
GNMK

0
GenMark Diagnostics Schedules Second Quarter Financial Results Conference Call for July 30, 2018

2018-07-16 globenewswire
CARLSBAD, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, July 30, 2018. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc.
GNMK

45
10 Strong Buy Stocks for Under $10 | InvestorPlace

2018-07-12 investorplace
Just because a stock is cheap doesn’t mean you should have to compromise on quality. These 10 Strong Buy stocks tick all the boxes. True, they are all trading for under $10, but they also represent compelling investing opportunities based on far more than just their price. I used TipRanks’ stock screener to purposefully scan for stocks with a Strong Buy consensus rating from analysts and top analysts alike.
RIGL GSM LC MCRB NYTAB AKAO RESN GLUU GNMK CLF

0
GenMark Diagnostics Starting To Deliver, But Consistency Is A Key Issue

2018-07-06 seekingalpha
GenMark needs to maintain some of the positive momentum it built from a strong flu season in Q1, though its very limited testing menu is a significant hurdle right now.
BMXXY GNMK

0
GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram Positive Panel

2018-06-28 globenewswire
CARLSBAD, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced submission of its ePlex Blood Culture ID – Gram Positive (BCID-GP) panel to the U.S. Food and Drug Administration (FDA). The BCID-GP panel is the first of three blood culture panels being developed on the ePlex sample-to-answer system, for the diagnosis and disease management of bloodstream infections that can lead to sepsis.
GNMK

0
GenMark Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference

2018-06-06 globenewswire
CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL.
GNMK

1
GNMK / GenMark Diagnostics, Inc. 8-K (Current Report)

2018-05-31 sec.gov
Document UNITED STATES
GNMK

0
GNMK / GenMark Diagnostics, Inc. SD

2018-05-31 sec.gov
Document
GNMK

0
GNMK / GenMark Diagnostics, Inc. S-8

2018-05-30 sec.gov
Document As filed with the Securities and Exchange Commission on May 30, 2018
GNMK

0
GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to today's conference call to discuss GenMark Diagnostics' First Quarter 2018 Financial Results. My name is Takia and I will be your operator on this call. After the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time. [Operator Instructions] Please note that this call is being recorded today, Tuesday, May 1, 2018 at 1.
GNMK

1
GNMK / GenMark Diagnostics, Inc. 10-Q (Quarterly Report)

2018-05-01 sec.gov
Document Table of Contents
GNMK

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 372309104